Searched for
ANTIBIOTIC APIS
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- Sakar Healthcare partners with Zydus Lifesciences for GCC MarketsSakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Market bets on Aurobindo as Europe, US sales show uptickAurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...
- Painkiller, antibiotic prices set for marginal increase starting April 1Starting April 1, the prices of essential medicines will experience an increase of 0.6%. This change aligns with the annual alterations in ...
- India pharma production hit by propane shortage; vitamin, hormone supply at riskIndia’s pharmaceutical industry is facing the risk of medicine shortages as a propane gas crunch forces several manufacturing units to part...
- Delius Pharma gets regulatory approval to import Ceftriaxone API from ChinaDelius Pharmaceuticals has secured approval from the CDSCO to import Ceftriaxone Sodium API from China's Guangxi Kelun Pharmaceutical. This...
- API prices fall sharply, easing pressure on India's pharmaceutical industryIndia's pharmaceutical industry is experiencing relief as active pharmaceutical ingredient (API) prices plummet due to overcapacity and agg...
- Indians' medical bills set to swell, here's whyThe sharp increase has been witnessed in high-volume key antibiotics including azithromycin and amoxicillin imported from China. "These are...
- Indian companies are paying up to 25 per cent more for China APIsKey APIs have become 12-25% costlier in the past few days amid possible supply disruptions that may squeeze margins and raise drug prices, ...
- China hikes prices of key drug ingredientsWhile increased prices will put cost pressure on the domestic industry over the next few months, more importantly it has sparked speculatio...
- Centre looking to hike import duty on bulk drugs, in bid to boost local manufacturingThe department of pharmaceuticals (DoP) is mulling the proposal as it pushes to make India self-reliant on APIs. A committee of experts for...
- China supplies over 80% of pharma raw materialsThe India-China border standoff has put the spotlight back on our near-total dependence on the dragon for crucial raw materials used in med...
- Covid-19 battle: Restrictions on drug export may be liftedOut of 13 drugs whose exports were restricted, the government is likely to lift the ban on five including paracetamol, tinidazole, metronid...
- Covid-19: Pharma companies ask Govt to lift API's export restrictionsPharmaceutical lobby groups have urged the government to lift restrictions on export of active pharmaceutical ingredients (APIs) and formul...
- Coronavirus: Department of Pharmaceuticals recommends ban on export of 12 drug formulations, ingredientsChina accounted for 67.56 per cent of India''s total imports of bulk drugs and drug intermediates at USD 2,405.42 million in 2018-19.
- Coronavirus: Health research body may suggest alternative medicinesA government-led expert panel has asked India’s top health research body to recommend alternative medicines or therapies for some antibioti...
- Covid-19 Impact: Pharma companies feel the pain as prices of key inputs shoot upAccording to the data available with Pharmaceutical Export Promotion Council (Pharmexcil), the cost of paracetamol has gone up from Rs 250-...
- FY12 revenues seen at Rs 750 cr: Harshit Savla, Aarti DrugsHarshit Savla, Jt Managing Director, Aarti Drugs, talks about the company's plans and growth expectations.
Load More
